Introduction
============

Malawi is a low-income country with an estimated population of 16 million in 2012.[@R1] In 2004, approximately 930 000 Malawians were thought to be infected with human immunodeficiency virus (HIV), with an estimated 100 000 new HIV infections occurring annually and around 170 000 people in immediate need of antiretroviral therapy (ART).[@R2] That year, the Malawian Ministry of Health decided to scale up ART nationwide.

Before the scale-up, only nine hospitals in the public sector were delivering ART to about 3000 patients and treatment was unstructured, few health-care workers had received formal training in ART and there were no national systems of monitoring, recording and reporting.[@R3] This paper discusses the achievements of the scale-up in the face of severe health-system constraints and highlights the lessons learnt and new challenges.

Public health approach
======================

The health ministry assumed responsibility for the national scale-up of ART, adhering strongly to the principle of equitable access to therapy for everyone in Malawi, regardless of geographical location or type of health facility in the area. The implementing partners and stakeholders, including the private sector, worked together with the HIV department of the health ministry to develop national scale-up plans and implement one standardized system to deliver and monitor ART.

An effective system was already in place for diagnosing HIV infection. Criteria were developed for starting ART, based on the World Health Organization's (WHO) clinical stage 3 and 4 disease, or a CD4+ T-lymphocyte count below 200 cells/μL. ART was to be delivered free of charge at all levels of the health service from central hospitals to local health centres, and the same methods were to be used for assessing patients for ART eligibility, initiating treatment, following-up patients, and monitoring, recording and reporting on treatment outcomes.

Plans for the initial and continued scale-up had clearly stated objectives and activities, with associated milestones and timelines, which provided a benchmark to assess implementation.[@R4] The objectives included providing long-term ART, monitoring treatment outcomes on a quarterly basis, ensuring patients took at least 95% of their scheduled drugs, and having 50% of patients alive and on ART at three years from starting therapy. The activities included setting up the government HIV department, ensuring HIV testing, organizing procurement and distribution of drugs, and implementing supervision.

From the start, the Global Fund to Fight AIDS, Tuberculosis and Malaria financially supported the scale-up and remained the main funder. While having only one funding source meant less funding overall, it made it easier for the country to develop and implement a uniform approach that best fitted the country's resources and infrastructure.

An intensive and innovative training schedule took place in the early months of 2004, focused on clinical officers and nurses learning the ART guidelines. The courses were country-wide, run by the HIV department and its partners, and focused on teaching health-care workers the ART guidelines, including how to monitor and do cohort reporting. All participants had to pass an examination with marks of at least 85%. Trained health workers were given checklists of activities to be undertaken when they returned to their facilities and were mandated to brief facility staff, the local government district headquarters and neighbouring health centres about ART. The HIV department carried out a formal structured accreditation of each ART facility before allowing health workers to start administering treatment. The accreditation included checking all the staff had been briefed, ensuring guidelines were in place, inspecting ART clinics and checking pharmacy security. The trainings were and continue to be done once for new sites, with shorter trainings repeated when new guidelines are developed and new treatment strategies are implemented and standardized.

To expand coverage, from 2004 onwards ART delivery was decentralized from hospitals to peripheral health centres, with responsibility for initiating treatment being devolved from doctors and clinical officers to also include medical assistants and nurses. This required dialogue and agreements with professional associations and regulatory bodies, after which guidelines about who could start patients on ART were included in subsequent editions of the national guidelines.

All ART facilities are responsible for quarterly reporting of cases and their treatment outcomes using ART patient treatment cards and patient registers. For facilities with a high burden of patients, a simple, real-time, touch-screen electronic medical record system has been introduced, with data entered by clinicians or nurses at the time of patient contact.[@R5] The record system provides enhanced decision support to health-care workers during patient encounters, and the system produces quarterly and cumulative cohort reports.

Every three months, representatives from the HIV department and its partners conduct supervisory and monitoring visits to all ART sites in the country. This is to ensure there is adherence to guidelines, to check and collect data for national reporting and to monitor drug stock levels to facilitate drug supply forecasting.[@R6] Operational research has been integrated into these supervisory visits, and country-wide data have been used to inform the programme in more detail about who is accessing ART and to provide answers to pertinent questions arising from field implementation and technical working groups.[@R3]

In the first few years of ART scale-up, the HIV department developed a system of drug forecasting and procurement. Facilities are graded according to the burden of disease in the community, based on HIV prevalence estimates, along with data on the number of new patients needing to start ART each quarter, the cumulative numbers of patients alive and ART drug stock levels.[@R7] If facilities run short of drugs, the quarterly supervisory visits ensure that drugs can be moved from well stocked to understocked facilities.

Achievements
============

Within six months of the launch of the scale-up plan, ART was being delivered at 19 health facilities within the public sector. In subsequent years, treatment was rapidly brought to scale in both the public and private sectors and by 31 December 2015, there were 716 ART clinics. Following national treatment protocols and using the standard monitoring system, public and private clinics had started a total of 872 567 new patients on ART, of whom 595 186 were alive and on ART by December 2015 ([Table 1](#T1){ref-type="table"}).[@R8] At 64 government clinics throughout the country, 532 707 patients had been registered for ART through the electronic medical record system. During the first five years, from 2004 to 2008, representatives never found drugs to be out of stock, either nationally or at individual sites.

###### Characteristics and outcomes of patients ever started on antiretroviral therapy in Malawi up to 31 December 2015

  Characteristic                                                  No. (%) of patients
  --------------------------------------------------------------- ---------------------
  **Total registered at ART clinics**                             1 091 656 (100)
  **Registration type^a^**                                        
  First-time ART                                                  872 567 (80)
  ART re-initiation                                               12 334 (1)
  ART transfer-in                                                 206 755 (19)
  **Sex**                                                         
  Male                                                            393 498 (36)
  Female                                                          698 158 (64)
  **Pregnancy status (*n* = 698 158)**                            
  Non-pregnant                                                    564 661 (81)
  Pregnant                                                        133 497 (19)
  **Age at ART initiation, years**                                
  ≥ 15                                                            997 286 (91)
  0--14                                                           94 370 (9)
  **Reason for starting ART**                                     
  Presumed severe HIV disease (infants)                           3 707 (\< 1)
  Confirmed HIV infection^b^                                      
    Stage 1 or 2                                                  488 873 (45)
    Stage 3                                                       487 560 (45)
    Stage 4                                                       103 674 (10)
  Other^c^                                                        7 842 (\< 1)
  **Primary outcome (*n* = 888 918)^d^**                          
  Alive and on ART (includes patients in transit between sites)   595 186 (67)
  Lost to follow-up                                               207 968 (23)
  Stopped ART                                                     4 293 (\< 1)
  Died                                                            81 471 (9)
  **Time of death, months after starting ART (*n* = 81 471)**     
  1                                                               19 542 (24)
  2                                                               12 275 (15)
  3                                                               7 393 (9)
  4+                                                              42 261 (52)

AIDS; acquired immunodeficiency syndrome; ART: antiretroviral therapy; HIV: human immunodeficiency virus; WHO: World Health Organization.

^a^ ART re-initiation refers to a patient who interrupted ART for 3 months or longer and then returned to treatment; ART transfer-in refers to a patient already on ART who transferred from one site to another.

^b^ WHO clinical stages: stage 1 or 2 (asymptomatic or with mild HIV-related symptoms and signs), stage 3 (severe HIV-related symptoms), stage 4 (AIDS-defining illnesses).

^c^ Includes patients started on ART for reasons outside of the guidelines and also patients for whom data are missing.

^d^ At 31 December 2015. The difference between the 1 091 656 clinic registrations and 888 918 outcomes is due to the more than 200 000 patients who transferred between sites and were therefore counted more than once.

Note: Inconsistencies arise in some values due to rounding.

Lessons learnt and challenges
=============================

The key to rapid and massive scale-up in a country with shortages of health-care workers and weak laboratory infrastructure was standardization and simplicity ([Box 1](#B1){ref-type="boxed-text"}). The current national ART guidelines,[@R9] first published in late 2003[@R4] and updated every two to three years since, lay out the simplified and standardized approach for ART delivery in clinics in both the public and private sectors.

###### Summary of main lessons learnt

-   Strong national leadership allowed the health ministry to implement standardized systems for staff training, accrediting health facilities and delivering and monitoring antiretroviral therapy.

-   A system of quarterly supervision and monitoring ensured that health facilities had stocks of drug supplies and adhered to national treatment guidelines.

-   The strategy to treat all HIV-infected pregnant and breastfeeding women (option B+) means that Malawi is well placed to manage the World Health Organization's recommended treat-all approach.

Challenges in the early stages of scale-up were the few children accessing ART, difficulties in managing patients with HIV-associated tuberculosis and high early death rates (i.e. in the first six months of ART). After identifying the causes, these issues have largely been overcome by changing to simpler ART regimens, educating communities about the need to get tested and assessed for ART at an earlier stage of immune suppression and ensuring all patients are started on both ART and co-trimoxazole at the same time.[@R10] Published studies from other countries, combined with locally generated operational research, convinced the HIV department that adjunctive co-trimoxazole, administered over a patient's lifetime before or at the time of ART, reduced early mortality.[@R11] Policy and practice changes followed in 2007--2008 and co-trimoxazole is now routinely incorporated into the programme's activities.

In 2010, Malawi was faced with implementing WHO's new guidance on prevention of mother-to-child transmission of HIV. Decisions about how to manage HIV-infected pregnant women depended on timely and reliable CD4+ testing.[@R12] With a limited capacity to achieve this, Malawi proposed a new strategy (option B+) to offer all HIV-infected pregnant and breastfeeding women lifelong ART regardless of WHO clinical stage or CD4+ count.[@R13] Option B+ was introduced in July 2011[@R9] and after the introduction, the large increase in women starting ART has brought challenges. These include large patient loads at antenatal clinics, the need to confirm all HIV-positive test results to minimize the risk of misdiagnosis, and retaining HIV-infected women on long-term treatment during breastfeeding and weaning.[@R14] Solutions to the challenges include giving women three-monthly appointments, providing more support for confirming HIV-positive results, and better education of staff and patients about the need for lifelong ART even when patients are feeling well.

New challenges are arising. First, many patients are lost to follow-up ([Table 1](#T1){ref-type="table"}), regardless of their time on ART. This may be partly due to poorer skills among the staff in peripheral facilities and omitting to notify when patients transfer between treatment sites. Second, a smaller percentage of patients (1%) are on second-line ART than may be expected (15--25%),[@R15] raising concerns about the failure to identify patients who might have failed first-line therapy. Third, the burden of quarterly country-wide supervision for the large number of sites (over 750) is growing, mainly due to the need for transport to the sites, for skilled supervisors, and for funding. Fourth, there is the problem of ensuring regular drug stocks now that more ART regimens and larger quantities of drugs are needed compared with 10 years ago. Fifth, there is the issue of recognizing and managing new threats to health for treated patients, such as from noncommunicable diseases that are emerging due to HIV and ART or from patients' ageing now that survival is prolonged.[@R16]

In 2014, the Joint United Nations Programme on HIV/AIDS declared the 90--90--90 treatment target to diagnose 90% of all people with HIV, provide antiretroviral therapy for 90% of those diagnosed and achieve viral suppression for 90% of those on treatment, by 2020. WHO guidance in 2015 recommended that ART be initiated in everyone living with HIV at any CD4+ count.[@R17] Malawi's implementation of option B+ makes the country well placed to embrace and manage WHO's treat-all approach.
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